Advertisement

Topics

Venous Thromboembolism - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Venous Thromboembolism - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 80-page report is available in PDF from $2000.

Venous Thromboembolism - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Venous Thromboembolism - Pipeline Review, H1 2015’, provides an overview of the Venous Thromboembolism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Venous Thromboembolism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Venous Thromboembolism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Venous Thromboembolism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Thromboembolism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Thromboembolism Overview 7
Therapeutics Development 8
Pipeline Products for Venous Thromboembolism - Overview 8
Pipeline Products for Venous Thromboembolism - Comparative Analysis 9
Venous Thromboembolism - Therapeutics under Development by Companies 10
Venous Thromboembolism - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Venous Thromboembolism - Products under Development by Companies 14
Venous Thromboembolism - Companies Involved in Therapeutics Development 15
Bayer AG 15
Daiichi Sankyo Company, Limited 16
Gamma Therapeutics, Inc. 17
GlycoMimetics, Inc. 18
Green Cross Corporation 19
Isis Pharmaceuticals, Inc. 20
Portola Pharmaceuticals, Inc. 21
Regado Biosciences, Inc. 22
Sanofi 23
Venous Thromboembolism - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
betrixaban - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
edoxaban tosylate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Gammarin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GCC-2107 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GMI-1271 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ISIS-FXIRx - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Lysimab - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
REG-2 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
rivaroxaban - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
semuloparin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Venous Thromboembolism - Recent Pipeline Updates 50
Venous Thromboembolism - Dormant Projects 69
Venous Thromboembolism - Discontinued Products 70
Venous Thromboembolism - Product Development Milestones 71
Featured News & Press Releases 71
Apr 15, 2015: Daiichi Sankyo’s Once-Daily Lixiana (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism in Switzerland 71
Mar 06, 2015: NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots 72
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for…

For more information open Venous Thromboembolism - Pipeline Review, H1 2015.

SKU: GMDHC6627IDB

Original Article: Venous Thromboembolism - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Venous Thromboembolism - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...